Jevtana® (cabazitaxel) – New warning
September 12, 2016 – The FDA approved a new update to the Warnings and Precautions section of the Jevtana (cabazitaxel) drug label regarding the risk of interstitial pneumonia/pneumonitis, interstitial lung disease and acute respiratory distress syndrome.
Download PDF
